Azithromycin improves asthma control, cuts exacerbations in children

11 Jun 2022
Azithromycin improves asthma control, cuts exacerbations in children

In the treatment of children with poorly controlled asthma, the use of azithromycin helps improve asthma control and reduce exacerbations, according to a study.

The study included 120 children aged 5–15 years who had poorly controlled asthma, which was defined as an Asthma Control Test (ACT) and Childhood Asthma Control Test (CACT) scores of ≤19. They were randomized to standard treatment alone (n=60) or in combination with azithromycin (10 mg/kg) three times weekly (n=60) for 3 months.

The mean age of the population was 9.9 years, and 74.16 percent were boys. The baseline parameters were similar between the groups. Compared with the control, azithromycin was associated with a significant increase in the primary outcome of ACT and CACT scores at 3 months (21.71 vs 18.33; p<0.001).

According to the GINA guidelines, the number of children with well-controlled asthma was much higher in the azithromycin group (41 out of 56) than in the control group (10 out of 56; p<0.001). Furthermore, the median number of exacerbations requiring emergency visit and steroid use was fewer in the azithromycin group (0 vs 1; p<0.001).

There were no significant between-group differences seen in Feno level, spirometry parameters, positive throat swab results, and adverse effects.

Editor's Recommendations